Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer

Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer

Bibliographic Details
Main Author:	N. Harbeck
Format:	Article
Language:	English
Published:	Elsevier 2021-04-01
Series:	Breast
Online Access:	http://www.sciencedirect.com/science/article/pii/S0960977621000497

Similar Items

Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer
by: Nadia Harbeck
Published: (2022-03-01)

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
by: Advani P, et al.
Published: (2015-09-01)

Neoadjuvant treatment of HER2-positive breast cancer: should therapy differ based on hormone receptor status?
by: Nadia Harbeck
Published: (2018-07-01)

Neoadjuvant–adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial
by: Liang Huang, et al.
Published: (2024-03-01)

Current neoadjuvant treatment options for HER2 positive breast cancer
by: Abdel-Razeq H, et al.
Published: (2011-08-01)

Neoadjuvant therapy for HER2-positive breast cancer
by: Nikolina Dukić, et al.
Published: (2019-06-01)

SA 8.2 Current adjuvant and neoadjuvant approaches
by: N. Harbeck
Published: (2023-03-01)

Optimizing (neo)adjuvant treatment of HER2-positive breast cancer
by: Reva K. Basho, et al.
Published: (2018-05-01)

Neoadjuvant systemic therapy of HER2-positive breast cancer
by: M A Frolova
Published: (2015-12-01)

<i>FGFR1</i> Amplification and Response to Neoadjuvant Anti-HER2 Treatment in Early HER2-Positive Breast Cancer
by: María Gaibar, et al.
Published: (2022-01-01)

Neratinib as extended adjuvant therapy in patients with HER2-positive/HR-positive early breast cancer: German HTA-driven analyses from the ExteNET study
by: D. Lüftner, et al.
Published: (2021-04-01)

Predictors of response to neoadjuvant treatment and changes to HER2 status in HER2-positive invasive breast cancer
by: LIU Jianlan, CHEN Daishi, HU Hong, ZHOU Dongxian, HU Jintao
Published: (2022-05-01)

Real world evidence of adjuvant trastuzumab in HER2 positive early breast cancer
by: J. Lluch-Gómez, et al.
Published: (2023-05-01)

Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer
by: Cláudia Vieira, et al.
Published: (2023-01-01)

<i>HER2</i> and <i>BARD1</i> Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment
by: Apolonia Novillo, et al.
Published: (2023-01-01)

Review of the status of neoadjuvant therapy in HER2-positive breast cancer
by: Gavin P. Dowling, et al.
Published: (2023-01-01)

Strategy and Status of Neoadjuvant Therapy for HER2-positive Breast Cancer
by: LIU Yunjiang, et al.
Published: (2024-01-01)

Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer
by: G. Griguolo, et al.
Published: (2021-03-01)

Benefits of neoadjuvant therapy compared with adjuvant chemotherapy for the survival of patients with HER2-positive breast cancer: A retrospective cohort study at FUSCC
by: Shuyue Zheng, et al.
Published: (2022-06-01)

Post-Neoadjuvant Treatment in HER2-Positive Breast Cancer: Escalation and De-Escalation Strategies
by: Natalia Krawczyk, et al.
Published: (2022-06-01)

P123 Optimal Regimen of Neoadjuvant Systemic Therapy for HER2 Positive Early Breast Cancer
by: C. Lo, et al.
Published: (2023-03-01)

BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer
by: Chau Dang, et al.
Published: (2022-05-01)

Extended adjuvant treatment of patients with HER2+ early breast cancer with neratinib: a multi-centric, prospective, non-interventional study (NIS) in Germany and Austria (ELEANOR)
by: R. Bartsch, et al.
Published: (2021-04-01)

Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab
by: Emanuela Ferraro, et al.
Published: (2022-03-01)

Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer
by: Shannon McLaughlin, et al.
Published: (2023-01-01)

Neoadjuvant Treatment with HER2-Targeted Therapies in HER2-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis
by: Agampodi Danushi M. Gunasekara, et al.
Published: (2022-01-01)

Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials.
by: Wenjin Yin, et al.
Published: (2011-01-01)

Efficacy and safety of neoadjuvant therapy for HER2-positive early breast cancer: a network meta-analysis
by: J. Zhang, et al.
Published: (2021-04-01)

Efficacy and safety of neoadjuvant therapy for HER2-positive early breast cancer: a network meta-analysis
by: Jie Zhang, et al.
Published: (2021-04-01)

Neoadjuvant and adjuvant treatment for triple negative breast cancer
by: L. Carey
Published: (2021-04-01)

Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer
by: Joohyun Hong, et al.
Published: (2022-06-01)

HER2-Positive Metaplastic Breast Cancer with Resistance to Neoadjuvant Chemotherapy: Case Report
by: Kaho Tateishi, et al.
Published: (2023-11-01)

Immune repertoire and responses to neoadjuvant TCHP therapy in HER2-positive breast cancer
by: Junyoung Shin, et al.
Published: (2023-02-01)

Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer
by: Li S, et al.
Published: (2018-09-01)

Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy
by: Claudia Omarini, et al.
Published: (2020-09-01)

Role of Post-Neoadjuvant therapy with trastuzumab emtansine in HER2-positive breast cancer
by: E. V. Lubennikova, et al.
Published: (2021-12-01)

Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade
by: M. C. Liefaard, et al.
Published: (2024-04-01)

Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer
by: Zheng-Jun Yang, et al.
Published: (2024-01-01)

Neoadjuvant chemotherapy with or without anthracyclines in combination with single HER2-targeted therapy in HER2-positive breast cancer
by: Anshul Gupta, et al.
Published: (2023-01-01)

Treatment of HER2 positive breast cancer patients
by: Erika Matos
Published: (2012-03-01)